Irregular antibodies in transfused patients and associated morbidity
https://orcid.org/0009-0006-1031-024X
The presence of irregular antibodies that differ from the natural antibodies of the immune system can cause severe hemolytic reactions that complicate future blood transfusions and endanger the patient's life. The objective of the study is to describe the irregular antibodies in transfused patients and associated morbidity, where the methodology applied is descriptive documentary narrative. The results show that, in North America, 48.8% of cases of alloimmunization occur. In Central America, a study in Mexico reported 43.3% of Anti-E, 35.8% of Anti-D and 20.9% of Anti-C. In South America, a study in Colombia revealed 50% Anti-E, 25% Anti-Kell and 25% Anti-C, while in Ecuador the most frequent irregular antibodies are 50% Anti-E and 25% Anti-Kell; blood transfusions for diseases such as anemia, leukemia, trauma, internal bleeding, obstetrics, spontaneous abortion present antibodies such as Anti-D and Anti-E. It is concluded that this study provides significant evidence that supports the need to improve strategies for the prevention and management of alloimmunization, which could contribute to optimizing the quality of life of transfused patients.
Ackfeld T, Schmutz T, Guechi Y, Le Terrier C. Blood Transfusion Reactions—A Comprehensive Review of the Literature including a Swiss Perspective. J Clin Med. 2022;11(10):2859.
Tormey C, Hendrickson J. Transfusion-related red blood cell alloantibodies: induction and consequences. Blood. 2020;133(17):1821–30.
Molina R, Gómez S, Vela J, Montiel LA, Reyes E. Pathophysiology of Alloimmunization. Transfusion Medicine and Hemotherapy. 2020;47(2):152–9.
Handa A, Kukar N, Maharishi R, Syal N, Arora H. Analysis of red cell alloimmunization in multi transfused patients at a Tertiary care teaching hospital. J Family Med Prim Care. 2020;9(6):2907.
Ali N, Matos A, Siguenza G, Cuevas B, Pavón R, Zaldivar E. Aloanticuerpos eritrocitarios en pacientes politransfundidos. Hematología. 2023;1(1).
García I, Cadena J. Reacción pos transfusional y anticuerpos irregulares en pacientes transfundidos en el Hospital General Martin Icaza. Babahoyo - 2023. MQRInvestigar. 2024;8(2):2519–31.
Cadena J, Solano C. Anticuerpos irregulares y grado de implicación en pacientes transfundidos del Hospital General San Francisco en Quito Periodo 2019-2023. MQRInvestigar. 2024;8(2):1348–63.
Handa A, Kukar N, Maharishi R, Syal N, Arora H. Analysis of red cell alloimmunization in multi transfused patients at a Tertiary care teaching hospital. J Family Med Prim Care. 2020;9(6):2907.
Yadav A, Raturi G, Aparna B. Prevalence of irregular red cell antibody in transfusion recipients vis-a-vis healthy blood donors attending a tertiary care hospital in North India. Asian J Transfus Sci. 2022;16(1):73–7.
Kuruvanplackal A, Soonam J, Indu K, Sasikala N, Sreenath S. PREVALENCE OF RED CELL ALLOANTIBODIES IN MULTI-TRANSFUSED HAEMATOLOGY PATIENTS IN A TERTIARY CARE CENTER. International Journal of Academic Medicine and Pharmacy. 2023;5(5):603–8.
Saha S, Krishna D, Prasath R, Sachan D. Incidence and Analysis of 7 Years Adverse Transfusion Reaction: A Retrospective Analysis. Indian Journal of Hematology and Blood Transfusion. 2020;36(1):149–55.
Abdullah S, Hassan M, Ramli M, Abdullah M, Mohd N. Red Blood Cell Alloimmunization and Its Associated Factors among Chronic Liver Disease Patients in a Teaching Hospital in Northeastern Malaysia. Diagnostics. 2023;13(5):886.
Viayna E, Gehrie E, Blanchette C, Meny G, Noumsi G, Huber M, et al. Red cell alloimmunization is associated with increased health care costs, longer hospitalizations, and higher mortality. Blood Adv. 2022;6(20):5655–8.
Laccourreye O, Maisonneuve H. French scientific medical journals confronted by developments in medical writing and the transformation of the medical press. Eur Ann Otorhinolaryngol Head Neck Dis. 2019;136(6):475–80.
Tormey C, Hendrickson J. Transfusion-related red blood cell alloantibodies: induction and consequences. Blood. 2019;133(17):1821–30.
Zarka C, Luo A, Mapombo S, Malinowski A, Kuo K, Shehata N, et al. Comparison of Alloimmunization in Pregnant People with Sickle Cell Disease Receiving Chronic Versus on-Demand Transfusions: A Multinational Study. Blood. 2023;142(Supplement 1):927–927.
Molina R, Gómez S, Vela J, Montiel L, Reyes E. Pathophysiology of Alloimmunization. Transfusion Medicine and Hemotherapy. 2020;47(2):152–9.
Higuita L, Flóresz J, Gómez A, Patiño J. Prevalencia de Anticuerpos Irregulares en Pacientes Transfundidos en MedellínColombia 2016-2018. Archivosdemedicina. 2019;15(22):1–8.
Caicedo G, Ortego F. Frecuencia e identificación de anticuerpos irregulares en pacientes politransfundidos en el hospital de especialidades Eugenio Espejo entre el 2018 y 2020. Ciencia Latina Revista Científica Multidisciplinar. 2023;7(1):1503–13.
Mejía B, Palomino R, Linares V, Jiménez M. Frecuencia de anticuerpos irregulares y factores asociados en pacientes con patología cardiaca. Revista Médica transfusional. 2019;11(1):11–21.
Angarita M, Urbano E, Cantor M. Anticuerpos irregulares en donantes de sangre. Revista Cubana de Hematología, Inmunología y Hemoterapia. 2021;37(4):1–23.
Benedetti V, Hellmann M, Cesaro M, Duarte A, Cauz M, Moresco R. FREQUÊNCIA DE ANTICORPOS IRREGULARES IDENTIFICADOS EM PACIENTES ATENDIDOS EM UM HEMONÚCLEO NO SUDOESTE DO PARANÁ NO ANO DE 2017. Arquivos de Ciências da Saúde da UNIPAR. 2020;24(3).
Thompson O, Ologbo O, Mathew E. Frequency, Pattern and Risk Factors for Red Blood Cell Alloimmunization in Multiply Transfused Cancer Patients in a Nigerian Tertiary Healthcare Facility in Nigeria. J Blood Disord Transfus. 2022;1–9.
Courbil R, Manteau A. Reglas de compatibilidad y accidentes inmunológicos de la transfusión sanguínea. EMC - Anestesia-Reanimación. 2020;46(2):1–10.
Thein S, Pirenne F, Fasano R, Habibi A, Bartolucci P, Chonat S, et al. Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal. Haematologica. 2020;105(3):539–44.
Escamilla J, Ríos M, Garza A, Monares E. Anemia grave e incompatibilidad sanguínea. Protocolo de actuación en situaciones de urgencia. Revista Mexicana de Patología Clínica y Medicina de Laboratorio. 2021;68(4):195–201.
Castillo M. Principales anticuerpos involucrados en la incompatibilidad sanguínea en México, de la estadística a la resolución. Revista Mexicana de Medicina Transfusional. 2022;14(S1):27–9.
Terrazas J, Rivera M, Carrera M, Santana V, Moreno V, Leal I, et al. Anticuerpos irregulares eritrocitarios detectados en el Centro Estatal de la Transfusión Sanguínea del Estado de Chihuahua, México. Rev Hematol Mex. 2019;19(3):109–14.
Wood E, McQuilten Z. Outpatient transfusions for myelodysplastic syndromes. Hematology. 2020;2020(1):167–74.
Karafin M, Westlake M, Hauser R, Tormey C, Norris P, Roubinian N, et al. Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study ( <scp>REDS</scp> ‐ <scp>III</scp> ) database. Br J Haematol. 2019;181(5):672–81.
Chaves W, Dueñas A, Madariaga C, Herrera S. Acerca de las reacciones hemolíticas tardías. Revista Repertorio de Medicina y Cirugía. 2023;32(3):261–4.
Marcante F, Schmitt B, Albuquerque A, Accorsi B, Rodrigues C. Prevalence of red blood cell alloimmunization in multiply transfused patients. Clinical and Biomedical Research. 2020;40(2):91–5.
Idrobo H, Bolívar N, Herrera J, Guerrero Á, Rincón É, Zorrilla C, et al. Frecuencia y tipificación de anticuerpos irregulares en un servicio de medicina transfusional nivel IV, Cali. Revista Colombiana de Hematología y Oncología. diciembre de 2019;4(2):25.
Flórez-Duque J, Gómez-Álvarez A, Patiño Carreño J, Cardona-Arias JA. Prevalencia de anticuerpos irregulares en donantes en un banco de sangre de Antioquia, 2016-2018. Ces Medicina. 2019;33(1):3–12.
Rolon M, Hoyos K, Correa A, Villegas R. Caracterización de donantes de sangre con rastreo de anticuerpos irregulares positivo en Montería, Colombia 2012-2015. Revista Cubana de Hematología, Inmunología y Hemoterapia. 2019;35(2):1–12.
Ulloa A, Crespo C, Chiriboga R. Prevalencia de anticuerpos anti-eritrocitarios en donantes voluntarios de sangre Ecuatorianos. Acta bioquímica clínica latinoamericana. 2019;53(3):323–30.
Acosta A, Yela T, Mina J. Incompatibilidad de anticuerpos eritrocitarios y su importancia en el diagnóstico inmunohematológico de anemias hemolíticas. MQRInvestigar. 2024;8(1):1610–31.
Al-Asmari B, Baothman A, Almohammadi M, Aljuaid M, Jastaniah W. Prevalence of Red Blood Cell Alloimmunization Among Pediatric Patients With Sickle Cell Disease in Saudi Arabia. J Pediatr Hematol Oncol. 2024;46(5):284–9.
Reyes M, Beniot S, García A, Rivero A, Fernández C. Confección y evaluación del panel celular para la liberación de hemoclasificadores. Laboratorio Nacional de Control. Hematología. 2023;1(1).
Wapukha Z, Wanjau T, Emonyi W, Marabi P. Risk factors for red blood cell alloimmunization in multi-transfused oncology patients at Moi Teaching and Referral Hospital, Kenya. Afr J Health Sci. 2023;36(3):326–36.
Zarka C, Luo A, Mapombo S, Malinowski A, Kuo K, Shehata N, et al. Comparison of Alloimmunization in Pregnant People with Sickle Cell Disease Receiving Chronic Versus on-Demand Transfusions: A Multinational Study. Blood. 2023;142(1):927–927.